A carregar...
Fulvestrant in the treatment of hormone receptor‐positive/human epidermal growth factor receptor 2‐negative advanced breast cancer: A review
Nearly 75% of breast cancers are hormone receptor‐positive (HR+) and human epidermal growth factor receptor type 2‐negative (HER2−), making endocrine therapy the mainstay of treatment for HR+ and HER2− combination. Although endocrine therapy, such as therapy with fulvestrant, is widely used in the c...
Na minha lista:
| Publicado no: | Cancer Med |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6536994/ https://ncbi.nlm.nih.gov/pubmed/31004402 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2095 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|